EAST RUTHERFORD, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Cambrex Corporation , a leading provider to the healthcare industry, is pleased to announce that David DeMarco, Ph.D., Vice President Strategic Planning has been appointed to the position of Vice President Strategy and Corporate Development. In addition to developing and implementing the global Cambrex business strategy, Mr. DeMarco will lead the Company’s activities related to acquisitions, partnerships and alliances.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )
“It makes sense to combine strategic and commercial development activities,” commented John R. Leone, Cambrex President and Chief Executive Officer. “Partnerships and acquisitions are an integral part of our growth strategy. By unifying the leadership of these two critical business functions, we can better align commercial development activities with the strategic plan and ensure acquisition candidates are consistent with meeting our strategic and financial objectives.”
“Dave is the right person for this assignment with his strong track record of strategic development, disciplined execution and experience growing organizations,” commented John R. Leone.
Mr. DeMarco joined Cambrex in April 2005 as Vice President, Strategic Planning. Prior to Cambrex he was with Sanofi-Aventis Dermatology where he created a commercialization positioning strategy and launched a portfolio of products worldwide. He also served as the Commercial Head for Europe where he set the organization on a turnaround path while implementing a series of new commercial practices.
Mr. DeMarco has a B.S. in Chemistry from Grove City College and a Ph.D. from Purdue University.
About Cambrex
Cambrex is a global, diversified life sciences company dedicated to providing products and services to accelerate and improve the discovery and commercialization of human therapeutics. The Company employs approximately 1900 worldwide. For more information, please visit http://www.cambrex.com.
Since the mid-1990’s, Cambrex has helped customers develop their active pharmaceutical ingredients (APIs) more efficiently and cost-effectively. The Company has diagnosed and overcome problems that clients had in their manufacturing processes, provided clinical or commercial quantities of hundreds of pharmaceutical products and provided the analytical, regulatory and other support services that clients need to shorten the time to market. More recently, the Company expanded into the product commercialization arena with sales and marketing services. The combined strength of experience, breadth of products and services and success integrating over twenty acquisitions supports the Company’s strategy to move into the specialty therapeutics market.
Photo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGOCambrex Corporation
CONTACT: Anne-Marie Hess, Sr. Director, Investor Relations & CorporateCommunications of Cambrex Corporation, +1-201-804-3062,annemarie.hess@cambrex.com
Web site: http://www.cambrex.com/
Company News On-Call: http://www.prnewswire.com/comp/134219.html /
